<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
"http://www.w3.org/TR/html4/strict.dtd">
<!--[if lt IE 7 ]><html class="ie ie6" lang="en"> <![endif]-->
<!--[if IE 7 ]><html class="ie ie7" lang="en"> <![endif]-->
<!--[if IE 8 ]><html class="ie ie8" lang="en"> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!--><html lang="en"> <!--<![endif]-->
<head>

	<!-- Basic Page Needs
  ================================================== -->
    <script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/jquery-1.8.3.min.js" type="text/javascript"></script>
    <script type="text/x-mathjax-config">
	MathJax.Hub.Config({
	  "HTML-CSS": { linebreaks: { automatic: true } },
	         SVG: { linebreaks: { automatic: true } }
	});
	</script>
    <script type="text/javascript" src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
	<meta charset="utf-8">
	<title>Genitourinary System</title>
	<meta name="description" content="Course Notes for Genitourinary System">
	<meta name="author" content="Kevan Lu">
	<meta name="robots" content="noindex,nofollow"/>
	
	<!-- Mobile Specific Metas
  ================================================== -->
	<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">

	<!-- CSS
  ================================================== -->
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/layout.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/content.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/print.css">
	<link href="http://maxcdn.bootstrapcdn.com/font-awesome/4.2.0/css/font-awesome.min.css" rel="stylesheet">	
	
	<script>
		(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
		(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
		m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
		})(window,document,'script','http://www.google-analytics.com/analytics.js','ga');		
		ga('create', 'UA-40381402-3', 'dropboxusercontent.com');
		ga('send', 'pageview');
	</script>

	<!-- Favicons
	================================================== -->
	<link rel="shortcut icon" href="https://dl.dropboxusercontent.com/u/157117/Class%20References/favicon.png" type="image/png">
</head>
<body>
    <div class="overlay"><h1><a style="border:none;" href="http://kevanlu.github.io/genitourinary">Genitourinary System</a></h1></div>
    <div class="sidebar-background"></div>
    <div class="sidebar">
        <!-- Displays a Search Bar-->
<div class="search-wrapper">
	<div class="index"><a href="http://kevanlu.github.io"><i class="fa fa-stethoscope"></i> Schulich Notes</a></div>
	<form class="search" action="http://kevanlu.github.io/genitourinary/search.html">
	<div style="float: left;"><input type="text" value="Search Genitourinary System" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" name="q" id="tipue_search_input"></div>
	<div style="float: left;"><input type="button" id="tipue_search_button" onclick="this.form.submit();"></div>
	<div style="clear: left;"></div>
	</form>
</div>

<div class="course-index">
	<a href="http://kevanlu.github.io/genitourinary">Genitourinary System</a>
</div>

        <nav>	
	<li class="week">Week 1</li>
	<ul>
		<li class="day">Monday, April 7</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/07/intro-case-week.html">Introduction &amp; Case of the Week</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/07/functional-anatomy-kidney.html">Functional Anatomy of the Kidney</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/07/embryology-kidney.html">Embryology of the Kidney</a></li></ul>
		<li class="day">Tuesday, April 8</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/08/histology-kidney.html">Histology of the Kidney</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/08/anatomy-urinary-tract-kidneys-ureters-adrenals.html">Anatomy of the Urinary Tract, Kidneys, Ureters, &amp; Adrenals</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/08/gfr-physiology.html">GFR Physiology</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/08/histology-urinary-tract.html">Histology of the Urinary Tract</a></li></ul>
		<li class="day">Wednesday, April 9</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/09/reabsorption-secretion-trip-down-tubule.html">Reabsorption &amp; Secretion</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/09/sodium-handling-kidney.html">Sodium Handling in the Kidney</a></li></ul>
		<li class="day">Thursday, April 10</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/10/edema-assessing-volume-status.html">Edema &amp; Assessing Volume Status</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/10/free-water-handling.html">Free Water Handling in the Kidney</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/10/hypernatremia.html">Hypernatremia</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/10/hyponatremia.html">Hyponatremia</a></li></ul>
		<li class="day">Friday, April 11</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/11/acid-base-physiology.html">Acid Base Physiology</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/11/acid-base-cases.html">Acid Base Cases</a></li></ul>
	</ul>
	<li class="week">Week 2</li>
	<ul>
		<li class="day">Monday, April 14</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/14/potassium-handling-kidney.html">Potassium Handling in the Kidney</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/14/cases-hypokalemia-hyperkalemia.html">Cases of Hypokalemia &amp; Hyperkalemia</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/14/iv-fluids.html">IV Fluids</a></li></ul>
		<li class="day">Tuesday, April 15</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/15/measurement-renal-function.html">Measurement of Renal Function</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/15/acute-kidney-injury-1.html">Acute Kidney Injury I</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/15/acute-kidney-injury-2.html">Acute Kidney Injury II</a></li></ul>
		<li class="day">Wednesday, April 16</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/16/anatomy-retriperitoneum.html">Anatomy of the Retroperitoneum</a></li></ul>
		<li class="day">Thursday, April 17</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/17/urinary-tract-obstruction.html">Urinary Tract Obstruction</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/17/acid-base-potassium-small-groups.html">Acid-Base &amp; Potassium Small Groups</a></li></ul>
	</ul>
	<li class="week">Week 3</li>
	<ul>
		<li class="day">Monday, April 21</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/21/chronic-kidney-disease.html">Chronic Kidney Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/21/proteinuria.html">Proteinuria</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/21/hematuria.html">Hematuria</a></li></ul>
		<li class="day">Tuesday, April 22</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/22/anatomy-pelvis.html">Anatomy of the Pelvis</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/22/vessels-nerves-pelvis.html">Vessels &amp; Nerves of the Pelvis</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/22/anatomy-development-male-genitalia.html">Anatomy &amp; Development of Male Genitalia</a></li></ul>
		<li class="day">Wednesday, April 23</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/23/case-diabetic-nephropathy.html">Case of the Week &ndash; Diabetic Nephropathy</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/23/diuretics-1.html">Diuretics I</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/23/diuretics-2.html">Diuretics II</a></li></ul>
		<li class="day">Thursday, April 24</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/24/approach-renal-mass.html">Approach to the Renal Mass</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/24/voiding-dysfunction-incontinence.html">Voiding Dysfunction &amp; Incontinence</a></li></ul>
		<li class="day">Friday, April 25</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/25/special-issues-pediatric-nephrology.html">Special Issues in Pediatric Nephrology</a></li></ul>
	</ul>
	<li class="week">Week 4</li>
	<ul>
		<li class="day">Tuesday, April 29</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/29/benign-prostate-hyperplasia.html">Benign Prostate Hyperplasia</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/29/prostate-cancer.html">Prostate Cancer</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/29/glomerulonephritis-utis-small-group.html">Glomerulonephritis &amp; UTIs Small Group</a></li></ul>
		<li class="day">Wednesday, April 30</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/30/urinary-tract-infections.html">Urinary Tract Infections</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/04/30/urology-small-group.html">Urology Small Group</a></li></ul>
		<li class="day">Thursday, May 1</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/01/tumours-lower-urinary-tract.html">Tumours of the Lower Urinary Tract</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/01/approach-scrotal-mass.html">Approach to the Scrotal Mass</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/01/renal-failure-sodium-disorders-small-group.html">Renal Failure &amp; Sodium Disorders Small Group</a></li></ul>
		<li class="day">Friday, May 2</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/02/case-kidney-transplantation.html">Case of the Week &ndash; Kidney Transplantation</a></li></ul>
	</ul>
	<li class="week">Week 5</li>
	<ul>
		<li class="day">Tuesday, May 6</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/06/special-issues-pediatric-urology.html">Special Issues in Pediatric Urology</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/06/trauma-urinary-tract.html">Trauma and the Urinary Tract</a></li></ul>
		<li class="day">Wednesday, May 7</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/07/nephrolithiasis.html">Nephrolithiasis</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/07/case-dialysis-patient.html">Case of the Week &ndash; Dialysis Patient</a></li><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/07/renal-replacement-therapies.html">Renal Replacement Therapies &ndash; Hemodialysis &amp; Peritoneal Dialysis</a></li></ul>
		<li class="day">Thursday, May 8</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/08/vesicoureteral-reflux-enuresis-small-group.html">Vesicouretal Reflux &amp; Enuresis Small Group</a></li></ul>
		<li class="day">Tuesday, May 13</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/genitourinary/2014/05/13/gu-final-exam-review.html">GU Final Exam Review</a></li></ul>
	</ul>
</nav>
    </div>
    <div class="content-offset">
        <div class="content-background"></div>
        <div class="content">
            <div class="single post">
                <!-- Post Layout -->
                <div class="title"><h1>Case of the Week &ndash; Kidney Transplantation</h1></div>
                <info datetime="2014-05-02">
                    <span class="author"><a href="https://dl.dropboxusercontent.com/u/157117/notes-reference/jekyll/_site/contributors.html#kevanlu">Kevan Lu</a></span>
                    <span class="date">Friday, May 02, 2014</span>
                </info>
                <div class="body"><h2 id='patient_case'><strong>Patient Case</strong></h2>

<ul>
<li>
<p>The patient likely had an X-linked recessive disease &#8594; women tended to be the carriers, and the males tended to get it.</p>
</li>

<li>
<p>Patient had slow damage to his glomeruli over time, caused by a genetic diseases &#8594; he likely had <strong>Alport Syndrome</strong>.</p>

<ul>
<li><em>Alport Syndrome</em> is a genetic disease where you have a mutation in <em>type-4 collagen</em>.</li>

<li>Type-4 collagen is an important part of the glomerular basement membrane, so abnormalities can exacerbate glomerular damage.</li>

<li>Type-4 collagen is also involved with other systems &#8594; for instance hearing loss due to ear involvement.</li>
</ul>
</li>
</ul>

<h2 id='exam_material'><strong>Exam Material</strong></h2>

<p><strong>The following stuff will be on the final exam!</strong></p>

<ol>
<li>
<p><em>Why even do a kidney transplant? What advantages does a kidney transplant have over dialysis?</em></p>

<ul>
<li><strong>Improved quality of life</strong> &#8594; dialysis is miserable.</li>

<li><strong>Mortality benefit</strong> &#8594; patients who get a transplant live longer than those on dialysis, since dialysis promotes vascular disease.</li>
</ul>
</li>

<li>
<p><em>Who is eligible for a kidney transplant?</em></p>

<ul>
<li>It used to be that you had to be on dialysis to be eligible for a kidney transplant.</li>

<li>But <em>this is no longer the case</em> &#8594; now we actually try to give a kidney transplant before the patient needs dialysis. This is called a <strong>pre-emptive kidney transplant</strong>.</li>

<li>Pre-emptive kidney transplants are <i>associated with better outcomes</i>!</li>

<li>This isn&#8217;t something that we do as often as a transplant for a patient on dialysis, but it is approved, and it&#8217;s something we&#8217;re trying to do more and more.</li>

<li>The most convenient way to do a pre-emptive kidney transplant is with a <strong>living donor</strong> &#8594; this <strong>does not have to be a family member</strong>.</li>

<li><em>We don&#8217;t approve of financial-enticement for kidney transplanation</em>.</li>
</ul>
</li>

<li>
<p><em>What is the definition of death when you&#8217;re donating an organ?</em></p>

<ul>
<li>
<p><strong>Brain death</strong> &#8594; <em>not cardiac death</em>.</p>
</li>

<li>
<p>We do take organs from patients with cardiac death too, but this must be done rapidly, before the organs are no longer viable.</p>
</li>

<li>
<p>As a result, <em>most organ donors are from brain death</em>!</p>
</li>

<li>
<p><em>Deceased donor kidney transplants do not work as well as living donor kidney transplants.</em></p>

<ul>
<li>Deceased donor transplants last 8-12 years.</li>

<li>Living donor transplants last 15-20 years.</li>
</ul>
</li>

<li>
<p><strong>Why is this the case?</strong></p>

<ul>
<li><strong>Cold-ischemic time</strong> &#8594; with a living kidney donor, since it&#8217;s planned in advance, often the transplant can occur instantaneously.</li>

<li>This <em>minimizes the cold-ischemic time</em>.</li>

<li>With a deceased donor-transplant, you have to put the organ on ice, wait for the cross-match result, wait to get the operation set up, and then perform the operation.</li>

<li>During this time, <em>some degree of necrosis occurs</em>!</li>

<li>The longer the cold-ischemic time, the worse the kidney function, and the shorter the graft survival is.</li>

<li><strong>Co-morbidities</strong> &#8594; often, deceased donors will have <em>other co-morbidities</em> that worsen the viability of their donated kidney.</li>
</ul>
</li>
</ul>
</li>

<li>
<p><em>Where is the kidney implanted?</em></p>

<ul>
<li>
<p><strong>Anterior abdominal cavity</strong> &#8594; it&#8217;s actually transplanted <em>extra-retro-peritoneally</em>!</p>

<ul>
<li>The <em>renal artery</em> is hooked up to the <em>external iliac artery</em>.</li>

<li>The <em>renal vein</em> is hooked up to the <em>external iliac vein</em>.</li>

<li>The <em>ureter</em> is hooked up to the <em>bladder</em>.</li>
</ul>
</li>

<li>
<p><strong>Why is it implanted in the abdominal cavity?</strong></p>

<ul>
<li><em>It&#8217;s easier to biopsy when you&#8217;re monitoring for rejection.</em></li>
</ul>
</li>

<li>
<p>You actually <i>leave the native kidney in there</i> &#8594; you don&#8217;t take it out! They eventually atrophy on their own.</p>
</li>
</ul>
</li>
</ol>

<h2 id='lecture_objectives'><strong>Lecture Objectives</strong></h2>

<ul>
<li>Understand the high morbidity and mortality associated with hemodialysis and peritoneal dialysis and how renal transplantation affects this.</li>

<li>Have an approach to understanding the basic immunology of rejection.</li>

<li>List the mechanism of action of the immunosuppressive agents.</li>
</ul>

<h2 id='immunology_review'><strong>Immunology Review</strong></h2>

<ul>
<li>
<p><strong>Immune System</strong>:</p>

<ul>
<li><em>Innate Immunity</em> &#8594; rapid response to invasion.</li>

<li><em>Acquired Immunity</em> &#8594; later mechanism involving memory B-cells (antibody production).</li>
</ul>
</li>

<li>
<p><strong>First Lines of Defense</strong>:</p>

<ul>
<li>Skin and mucous membranes.</li>

<li>Secretion from sweat and sebaceous glands.</li>

<li>Tears.</li>
</ul>
</li>

<li>
<p>Immune cells arise from <em>hematopoiesis in the bone marrow</em>.</p>
</li>

<li>
<p>They communicate via surface molecules and <em>cytokines</em>.</p>
</li>
</ul>
<img src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/t-_dhzwv.png' />
<ul>
<li>
<p>With transplantation, the immune response arises from cells of <em>lymphoid origin</em>:</p>

<ul>
<li><strong>T-Cells</strong> &#8594; most common. <em>Acute Cellular Rejection</em>.</li>

<li><strong>B-Cells</strong> &#8594; less common. <em>Antibody-mediated Rejection</em>.</li>
</ul>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li><strong>T-Cells</strong> are involved in <strong>Acute Cellular Rejection</strong>, which is the <em>most common</em>.</li>

<li><strong>B-Cells</strong> are involved in <strong>Antibody-mediated Rejection</strong>, which is <em>more difficult to deal with</em>.</li>
</ul>
</blockquote>

<ul>
<li>
<p>Recall that:</p>

<ul>
<li><em>B-cells</em> produce antibodies.</li>

<li><em>T-cells</em> see foreign antigens expressed on APCs, and become activated and directly attack pathogens.</li>
</ul>
</li>
</ul>
<img src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/rvhl6pdu.png' />
<h1 id='case_study'>Case Study</h1>
<hr />
<blockquote>
<h4 id='case_summary_mr_mini_mintoo'><strong>Case Summary: Mr. Mini Mintoo</strong></h4>

<ul>
<li>32 year old Canadian gentleman of East Indian Background.</li>

<li>ESRD from chronic obstructive nephropathy.</li>

<li>On hemodialysis for the last 2 years.</li>

<li>Otherwise no significant medical problems.</li>
</ul>
</blockquote>

<ul>
<li>
<p>Called to Transplant Unit for a deceased donor renal transplant.</p>

<ul>
<li>No blood transfusions, previous transplants.</li>

<li>Panel reactive antibodies (PRA) 0%.</li>

<li>Donor and recipient are CMV and EBV IgG negative.</li>
</ul>
</li>

<li>
<p>We will see that this means that the patient is <em>very low risk</em>!</p>
</li>
</ul>

<h2 id='questions'><strong>Questions</strong></h2>

<ul>
<li>
<p><em>Why is having no blood transfusions, previous transplants, or pregnancies (in women) important?</em></p>

<ul>
<li>
<p>It&#8217;s <i>less likely that the patient will have developed antibodies.</i></p>
</li>

<li>
<p>Recall that we have HLA (Human Leukocyte Antigen) antigens on all our cell surfaces, which are used to identify <em>self from non-self</em>.</p>

<ul>
<li>Recall that Class I MHC (HLA) was on all nucleated cells.</li>

<li>Recall that Class II MHC (HLA) were on APCs only.</li>
</ul>
</li>

<li>
<p>If you form antibodies against foreign HLAs, then you&#8217;ll develop <strong>antibody-mediated rejection</strong>, as mentioned before.</p>
</li>

<li>
<p>This is much more difficult to treat than T-cel mediated rejection.</p>
</li>
</ul>
</li>

<li>
<p><em>How do you detect antibodies against a donor HLA?</em></p>

<ul>
<li>
<p>You want to see if there&#8217;s a reaction between the <strong>recipient antibodies</strong> and the <strong>donor HLAs</strong></p>

<ul>
<li>Lymphocytes express both HLA I &amp; II, so you&#8217;d <em>isolate the donor lymphocytes</em>.</li>

<li>The antibodies are in the plasma, so you&#8217;d <em>extract the recipient plasma</em>.</li>
</ul>
</li>

<li>
<p>So we <strong>mix donor lymphocytes with recipient plasma</strong>, and add a dye + complement to look for a WBC destruction.</p>
</li>

<li>
<p>This is called <strong>cross-matching</strong>.</p>
</li>

<li>
<p>A <em>positive cross-match is an absolute contraindication for a kidney transplant</em>!</p>
</li>
</ul>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li>A <strong>positive cross-match</strong> (antibodies against the donor HLA) is an <strong>absolute contraindication for a kidney transplant!</strong></li>
</ul>
</blockquote>

<ul>
<li>
<p><em>What are Panel Reactive Antibodies?</em></p>

<ul>
<li>They&#8217;re an <i>assessment of immunologic risk</i>, that can be regularly done without a potential donor.</li>

<li>We take a blood sample from 15 volunteers to act as theoretical donors, which will encompass the majority of HLA types.</li>

<li>We isolate their white cells, and do a cross-match against the serum of all the patients on the wait-list.</li>

<li><em>If none of the panel is destroyed, then you&#8217;re low risk.</em></li>
</ul>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li>The <strong>PRA (Panel Reactive Antibody)</strong> screen helps you <em>assess risk</em>, by cross-matching across a sample of theoretical donors.</li>

<li>A <em>low PRA score</em> suggests that you&#8217;re low risk!</li>
</ul>
</blockquote>

<ul>
<li>
<p><em>Why do you care that the patient is CMV and EBV IgG negative?</em></p>

<ul>
<li>
<p>The patient will be on immunosupressants, so they&#8217;ll be susceptible to infection if the donor has had a CMV or EBV infection.</p>
</li>

<li>
<p>If the donor has CMV or EBV, since herpesviruses can lie latent in nerves of the body, it can be transplanted to the recipient!</p>

<ul>
<li>Recall that <em>CMV in the immunosuppressed can be very serious!</em></li>

<li>Recall that <em>EBV in the immunosuppressed can transition to lymphoma!</em></li>
</ul>
</li>
</ul>
</li>

<li>
<p><em>We need the blood types of the donor and recipient to be compatible. Why is this the case?</em></p>

<ul>
<li>We&#8217;re only transplanting the organ, and not the blood. So why do we need the blood type to be the same?</li>

<li>The A-antigen or the B-antigen are <em>expressed on the blood vessels of the kidney</em>.</li>

<li>So if you do an <em>ABO-incompatible transplant</em>, you&#8217;ll have a <strong>hyperacute rejection</strong>, causing almost immediate graft-loss, and probable death.</li>
</ul>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li>To perform a transplant, you need the <strong>blood types to be compatible</strong> and you need the <strong>cross-match to be negative</strong>!</li>
</ul>
</blockquote>

<ul>
<li>
<p><em>Why do we need immunosuppression and what is your immunosuppression of choice?</em></p>

<ul>
<li>
<p>We need immunosuppression to prevent both <em>acute rejection</em> and <em>chronic rejection.</em></p>
</li>

<li>
<p>Note that if we have <strong>identical twins</strong>, then we <em>don&#8217;t need to use immunosuppression</em> &#8594; the body will recognize the organ as self!</p>

<ul>
<li>These kidneys will last until the patient dies, unless they get a <i>recurrence of their original disease</i>.</li>
</ul>
</li>
</ul>
</li>

<li>
<p><em>What is the most common cause of acute rejection?</em></p>

<ul>
<li>The most common cause of <em>acute rejection</em> is <strong>T-Cell mediated rejection</strong>.</li>
</ul>
</li>
</ul>

<h1 id='immunosuppression_posttransplantation'>Immunosuppression Post-transplantation</h1>
<hr />
<ul>
<li>
<p>Graft survival post-transplantation was pretty crappy until the 1980&#8217;s, when <em>cyclosporine was introduced</em>.</p>
</li>

<li>
<p><strong>Cyclosporine revolutionized things!</strong></p>
</li>

<li>
<p>1 year graft survival improved to 80% &#8594; which was a tremendous incrase.</p>
</li>

<li>
<p>Cyclosporine is a <strong>calcineurin inhibitor</strong> (aka <em><abbr title='Calcineurin Inhibitors'>CNI</abbr></em>).</p>

<ul>
<li>Recall that calcineurin inhibition blocks movement of NFAT through the nuclear membrane, ultimately <em>blocking T-Cell activation</em>.</li>

<li>Can&#8217;t activate T-Cells &#8594; no acute T-cell mediated rejection!</li>
</ul>
</li>

<li>
<p>At present, we have newer calcineurin inhibitors, such as <strong>Tacrolimus</strong>.</p>

<ul>
<li>Tacrolimus has an <em>even smaller risk of rejection!</em></li>
</ul>
</li>
</ul>

<h3 id='mechanism_of_action_of_calcineurin_inhibitors'><strong>Mechanism of Action of Calcineurin Inhibitors</strong></h3>

<ol>
<li>Calcineurin inhibitors block calcineurin, which is a <em>phosphatase</em> that dephosphorylates NFAT (Nuclear Factor of Activated T-Cells).</li>

<li>Since calcineurin can no longer dephosphorylate NFAT, NFAT cannot get into the nuclear membrane.</li>

<li>This prevents NFAT from upregulating transcription of several key genes for T-cell activation, particularly <em>IL-2</em>, which, as we recall, was critical for T-cell proliferation.</li>

<li>The net result is a <em>blocking of T-cell activation</em>.</li>
</ol>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li><strong>Cyclosporine</strong> and <strong>Tacrolimus</strong> are both <strong>calcineurin inhibitors</strong> (<abbr title='Calcineurin Inhibitors'>CNI</abbr>), which <em>block T-cell activation</em>.</li>

<li><em>Tacrolimus is more powerful.</em></li>
</ul>
</blockquote>

<h3 id='drugs_used_posttransplantation'><strong>Drugs used Post-Transplantation</strong></h3>

<ul>
<li>
<p>The typical complement of drugs after transplantation consists of <em>three medications</em>:</p>

<ol>
<li>
<p><strong>Calcineurin Inhibitors</strong> &#8594; eg. cyclosporine and tacrolimus.</p>
</li>

<li>
<p><strong>Prednisone</strong></p>
</li>

<li>
<p><strong>Mycophenolate</strong> (MMF, Cellcept) &#8594; blocks nucleotide synthesis, inhibiting T-cell amplification.</p>

<ul>
<li>
<p>This also affects rapid division in other organs, much like we see with chemotherapy for cancer.</p>
</li>

<li>
<p>The two most common side-effects due to this are:</p>

<ol>
<li><em>Gut Problems</em> &#8594; severe diarrhea, nausea, etc.</li>

<li><em>Bone Marrow Problems</em> &#8594; anemia, thrombocytopenia, leukopenia, etc.</li>
</ol>
</li>
</ul>
</li>
</ol>
</li>

<li>
<p>Patients will be on <em>heavy immunosuppression</em> for the first year, where the risk of rejection is highest.</p>
</li>

<li>
<p>After that, the body begins to acclimate to the new organ, and the risk of rejection falls. At this point, we can begin to lower the dosage of immunosuppression.</p>
</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li>
<p>A patient post-transplantation must be on the <em>following 3 medications</em>:</p>

<ol>
<li><strong>Prednisone</strong></li>

<li><strong>Calcineurin Inhibitor</strong> (Cyclosporine or Tacrolimus).</li>

<li><strong>Mycophenolate</strong> (MMF).</li>
</ol>
</li>

<li>
<p>All 3 affect the function of <em>T-cells</em>, preventing <em>acute-cellular rejection</em> (the most common type of rejection).</p>
</li>

<li>
<p><em>Mycophenolate (MMF)</em> can cause GI and BM side-effects.</p>
</li>
</ul>
</blockquote>

<h3 id='cni_renal_syndromes_of_toxicity'><strong><abbr title='Calcineurin Inhibitors'>CNI</abbr> Renal Syndromes of Toxicity</strong></h3>

<ul>
<li>
<p>Ironically, <strong>calcineurin inhibitors are nephrotoxic</strong>.</p>
</li>

<li>
<p>So even though we need them to avoid rejection, they themselves cause kidney damage!</p>
</li>

<li>
<p>Hence, we have to <em>carefully monitor drug dosage</em> to avoid drug toxicity.</p>
</li>

<li>
<p><strong>Acutely</strong>:</p>

<ul>
<li><em><i>Like NSAIDs</i></em>, <abbr title='Calcineurin Inhibitors'>CNI</abbr>s <em>vasoconstrict the afferent arteriole</em>, which drops the GFR and triggers a pre-renal state.</li>

<li>So if you see a kidney transplant with an elevated creatinine, don&#8217;t immediately suspect rejection &#8594; suspect excess calcineurin inhibitor.</li>

<li>With extremely high <abbr title='Calcineurin Inhibitors'>CNI</abbr> levels, you can actually get <abbr title='Acute Tubular Necrosis'>ATN</abbr>.</li>

<li>In extremely rare cases, you can actually get acute microvascular disease (<abbr title='Thrombotic Thrombocytopenic Purpura'>TTP</abbr> &#8594; Thrombotic Thrombocytopenic Purpura).</li>
</ul>
</li>

<li>
<p><strong>Chronically</strong>:</p>

<ul>
<li><abbr title='Calcineurin Inhibitors'>CNI</abbr>s cause <em>scarring</em>, causing a chronic (permanent) progressive decrease in GFR.</li>
</ul>
</li>
</ul>

<h2 id='sirolimus'><strong>Sirolimus</strong></h2>

<ul>
<li>Sirolimus, don&#8217;t need to know this.</li>

<li>Promising, hoped to replace calcineurin inhibitors.</li>

<li>Macrolide (rapamycin, recall mTOR). Other macrolides azithromycin, erythromycin, clarithromycin.</li>

<li>Directly inhibits cell-cycle, like mycophenylate.</li>

<li>Not nephrotoxic like <abbr title='Calcineurin Inhibitors'>CNI</abbr>s.</li>

<li>The problem is that this increases the acute rejection rate.</li>

<li>Stop using this!</li>

<li>Sometimes used in patients long after their transplantation, when their acute rejection risk is low, and the <abbr title='Calcineurin Inhibitors'>CNI</abbr> is causing kidney damage.</li>
</ul>

<blockquote>
<h4 id='remember'><strong>Remember</strong></h4>

<ul>
<li>Only used when acute rejection risk is low, and see nephrotoxicity from <abbr title='Calcineurin Inhibitors'>CNI</abbr>s.</li>
</ul>
</blockquote>

<h2 id='atgam_and_thymoglobulin'><strong>ATGAM and Thymoglobulin</strong></h2>

<ul>
<li>
<p>Very powerful antibodies to Tx acute rejection.</p>
</li>

<li>
<p>2 things we do with acute rejection (just like with RPGN):</p>

<ol>
<li><strong>High dose steroids.</strong></li>

<li><strong>Powerful antibody to get rid of T-Cells</strong> (thymoglobulin).</li>
</ol>
</li>

<li>
<p>Thymoglobulin, antibodies against human lymphoid tissue, developed in rabbits. The rabbits develop Abs against every human lymphoid marker! Gives you HIV-like CD4 cells.</p>
</li>

<li>
<p>Pretty serious, so thymoglobulin is only used when you have a severe rejection!</p>
</li>

<li>
<p>ATGAM</p>
</li>

<li>
<p>Immunization of horses with human lymphoid material</p>
</li>

<li>
<p>Thymoglobulin</p>
</li>

<li>
<p>Immunization of rabbits with human lymphoid tissue</p>
</li>

<li>
<p>These polyclonal antibodies contain cytotoxic antibodies against a variety of T cell markers</p>
</li>

<li>
<p>Depletion of peripheral lymphocytes</p>
</li>

<li>
<p>Side effects include fever, chills, arthralgias, anaphylaxis, hematologic toxicity, infection, malignancy</p>
</li>

<li>
<p>Mr. Mini Mintoo</p>
</li>

<li>
<p>Feeling great post transplant, but unfortunately 10 days post transplant develops increase in serum creatinine and renal biopsy confirms mild to moderate rejection</p>
</li>

<li>
<p>Drug levels are therapeutic</p>
</li>

<li>
<p><em>What are causes of AKI in a patient 10-days post transplant?</em> 1. <em>Calcineurin-inhibitor associated nephrotoxicity.</em> - Recall that <abbr title='Calcineurin Inhibitors'>CNI</abbr>s can cause afferent vasoconstriction, leading to a prerenal state. - Since his drug level was therapeutic, this probably isn&#8217;t the case. 2. <em>Acute Rejection</em>:</p>

<pre><code>- Could be both cellular or anti-body mediated, but as said before, the T-cell mediated rejection is more common.</code></pre>
</li>

<li>
<p>Approach the kidney transplant patient like any other patient with an AKI!</p>

<ul>
<li>
<p>Look for <em>prerenal, renal, or post-renal causes</em>.</p>
</li>

<li>
<p><strong>Prerenal</strong> &#8594; volume contraction.</p>
</li>

<li>
<p><strong>Renal</strong> &#8594;</p>
</li>

<li>
<p><strong>Post-renal</strong> &#8594; U/S with doppler.</p>

<ul>
<li>Recall that we implanted the kidney and reconnected all the vessels to the external iliac artery and vein.</li>

<li>Might have abnormal connection.</li>

<li>Doppler looks for normal blood flow at these attachment points.</li>
</ul>
</li>
</ul>
</li>
</ul>
<img class='right' src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/f7osa958.png' />
<ul>
<li>
<p>This patient has acute rejection.</p>
</li>

<li>
<p>T-cells are the dark purple dots.</p>
</li>

<li>
<p>Some have infiltrated the tubules &#8594; mild rejection.</p>
</li>

<li>
<p>Severe rejection &#8594; also infiltrated the blood vessels.</p>
</li>

<li>
<p>So if only in the interstitium/tubules &#8594; <em>mild rejection</em>.</p>
</li>

<li>
<p>Patient is on Mycophenolate, Prednisone, and Tacrolimus.</p>

<p>What&#8217;s our approach? Not severe rejection, so wouldn&#8217;t give thymoglobulin.</p>

<ol>
<li><strong>High-Dose Steroids</strong> (Prednisone).</li>

<li>Switch to Tacrolimus if on Cyclosporine. (switch to more potent <abbr title='Calcineurin Inhibitors'>CNI</abbr>)</li>

<li>If already on Tacrolimus, just give high dose prednisone.</li>
</ol>
</li>

<li>
<p>Mr. Mintoo has a great response to your choice of therapy and his creatinine comes down from a peak of 250 to 140.</p>
</li>

<li>
<p>He is discharged home. <hr /></p>
</li>

<li>
<p>Over the next 8 years gradual decline in renal function.</p>
</li>

<li>
<p>Creatinine is now 300 and progressively climbing.</p>
</li>

<li>
<p>Mr. Mintoo undergoes a renal biopsy.</p>
</li>
</ul>

<p>Progressive Chronic Kidney Disease.</p>

<ul>
<li>
<p>No rejection - don&#8217;t see T-cells or inflammatory cells.</p>
</li>

<li>
<p>Just see scarring.</p>
</li>

<li>
<p>CHRONIC RENAL REJECTION = scarring.</p>
</li>

<li>
<p>Why does this happen? - Immune-independent factors. - Diabetes. - Hypertension. - Drug Toxicity.</p>

<pre><code>- Recall chronic CNI Toxicity.</code></pre>

<ul>
<li>
<p>Immune-dependent factors.</p>

<ul>
<li>Chronic humoral rejection.</li>

<li>Recall that this presents much differently from acute rejection.</li>

<li>We have no good Tx for this. Tx good for acute rejection, bad for chronic rejection.</li>
</ul>
</li>
</ul>
</li>

<li>
<p>The patient has chronic allograft nephropathy</p>

<ul>
<li>Need to control and manage hypertension and diabetes</li>
</ul>
</li>

<li>
<p>The patient is initiated on sirolimus and his tacrolimus is weaned off</p>
</li>

<li>
<p>Mr. Mintoo is now maintained on sirolimus, prednisone and MMF</p>

<ul>
<li>On sirolimus, prednisone and MMF, Mr. Mintoo creatinine settles down at 200 and he is doing well</li>
</ul>
</li>
</ul>

<blockquote>
<h4 id='additional_information'><strong>Additional Information</strong></h4>

<ul>
<li>While on a trip in India, he consumes some samosas that light him on fire.</li>

<li>He develops a severe gastroenteritis that lasts 2 weeks and he has been unable to take his immunosuppressive medications.</li>

<li>He takes an emergency flight back to London and in clinic his creatinine is 600.</li>

<li>He does not respond to volume resuscitation and he receives a renal biopsy.</li>
</ul>
</blockquote>

<ul>
<li>We see severe rejection!</li>

<li>Start him on dialysis. Why didn&#8217;t we treat him with thymoglobulin first?</li>

<li>He already has crappy kidney, with high creatinine. Odds of restoring kidney function low, odds of killing him with severe immune suppression high, with concomitant infection!</li>
</ul>

<p>What if his creatinine was 80, and he had no scar? And this was an acute case.</p>

<ul>
<li>
<p><em>High dose prednisone.</em></p>
</li>

<li>
<p>Then you would treat it with <em>thymoglobulin</em>.</p>
</li>

<li>
<p>If could be antibody-mediated rejection (humoral component), then we still give <em>thymoglobulin + prenisone</em>, but we add in PLASMAPHORESIS (remove antibody from blood), and IVIG, which mops up the excess antibodies.</p>
</li>

<li>
<p>If all else fails, we used to consider doing a splenectomy.</p>
</li>

<li>
<p>But now with the introduction of <strong>rituximab</strong>, anti-CD20 Abs.</p>

<ul>
<li>Targets B-Cells, diminishing anti-donor Abs.</li>

<li>Recall we saw this in blood, to treat B-cell Non-Hodgkin&#8217;s Lymphomas.</li>
</ul>
</li>

<li>
<p>What do you need to remember?</p>

<ul>
<li>Transplantation &gt; dialysis.</li>

<li>Calcineurin inhibitors are good.</li>

<li>Patients will be on 3 immunosuppressant meds: prednisone, <abbr title='Calcineurin Inhibitors'>CNI</abbr>, mycophenolate (MMF).</li>

<li>Can get transplant without being on dialysis.</li>

<li>Living kidney transplants (don&#8217;t have to be related) better than deceased.</li>
</ul>
</li>
</ul>                
                </div>
            </div>
            <div class="pagination">
                <div style="width:50%; float:left;">
                     
                        <a class="newer" href="http://kevanlu.github.io/genitourinary/2014/05/01/renal-failure-sodium-disorders-small-group.html"><i class="fa fa-angle-left"></i> Renal Failure &amp; Sodium Disorders Small Group</a> 
                     
                </div>
                <div style="width:50%; float:right;">
                     
                        <a class="older" href="http://kevanlu.github.io/genitourinary/2014/05/06/special-issues-pediatric-urology.html">Special Issues in Pediatric Urology <i class="fa fa-angle-right"></i></a> 
                     
                </div>
            </div>
        </div>
    </div>
    <script src="http://kevanlu.github.io/genitourinary/index.js" type="text/javascript"></script>
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/search.css">	
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/tipuesearch_set.js" type="text/javascript"></script>
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/tipuesearch.js" type="text/javascript"></script>

<script>
$(document).ready(function() {
     $('#tipue_search_input').tipuesearch();
});
</script>
</body>
</html>